期刊文献+

嘧啶核苷磷酸化酶与原发性肝癌预后的关系

The Expression of Pyrimidine Nucleoside Phosphorylase(PyNPase) in Primary Hepatocellular Carcinoma and Its Clinical Significances in Prognosis
下载PDF
导出
摘要 目的初步探讨嘧啶核苷磷酸化酶在原发性肝癌中表达的临床预后意义。方法随机从我院外科2001年6月~2004年6月间185例原发性肝癌手术切除标本中随机抽取40例。术前均未经任何放化疗。使用SP免疫组化法分别检测肝癌细胞中PyNPase的表达。对所有病例的AFP水平,瘤体直径,门脉癌栓,转移复发率进行回顾性分析。结果①PyNPase的表达与肝癌Edmondson病理分级正相关。②PyNPase的表达与是否有PVTT、是否有肝内转移、淋巴结转移、肿瘤大小有关系,而与AFP水平、HbsAg阳性率无关。结论PyNPase在原发性肝癌组织中的表达水平除了对手术后的药物治疗有指导意义,其表达对肿瘤的预后有一定的提示意义。 Objective To investtgate the clinical significances in prognosis of the expression of Pyrimidine Nucleoside Phosphorylase(PyNPase) in primary hepatocellular carcinoma. Methods From Jun. 2001 to Jun. 2004, in 185 cases underwent hepatectomy for hepatocellular carcinoma,40 specimens were random ly selected as the experimental group, lnmunohistochemical staining had been used to detect the expression of PyNPase. Results ① There shows significant positive correlation between expression of PyNPase and the Edmondson's histological classification of HCC. ② There shows significant correlation between the expression of PyNPase and the existence of PVTT, LN metastasis, and diameter of the mass, but no correlation were found between the expression of PyNPase and the level of AFP and infective rate of hepatitis B. Conclusion The expression of PyNPase suggests the chemotherapeutic sensitive trend and the pronosis of HCC.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2006年第1期59-61,共3页 Cancer Research on Prevention and Treatment
关键词 原发性肝癌 嘧啶核苷磷酸化酶 转移复发 预后 Hepatocellular carcinoma Pyrimidine Nucleoside Phosphorylase(PyNPase) Pronosis
  • 相关文献

参考文献6

  • 1李文滨,王捷.原发性肝癌细胞中Py NPase的表达及其临床意义[J].岭南现代临床外科,2005,5(1):69-70. 被引量:1
  • 2Fox-SB, Moghaddam-A, Westwood-M Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study [J]. J-Pathol, 1995, 176(2): 183-190.
  • 3Yamamoto A, Dhar DK, EI Assal ON. Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma[J]. J Hepatol, 1998, 29(2): 290-299.
  • 4王宝成,毕经旺,李志.靶向化疗——氟化嘧啶类药物的研究进展[J].国外医学(肿瘤学分册),2001,28(6):447-451. 被引量:73
  • 5Jun TK. Platelet derived endothelial cell growth factor has thymidine phosphorylase activity [J]. Biochem-Biophys-Res-Commun, 1992, 184(3): 1311-1316.
  • 6Shinsuke, EI Assal ON. Thymidine phosphorylase(platelet-derived endothelial cell growth factor),microvessel density and clinical outcome in hepatocellular carcinoma[J].J-Hepatol,1998, 29(2): 290-299.

二级参考文献17

  • 1Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
  • 2Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
  • 3Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
  • 4Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
  • 5Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
  • 6Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
  • 7Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104.
  • 8Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493.
  • 9O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406.
  • 10O'Reilly SM,Moiseyenko V,Talbot DC, et al. A randomized phase Ⅱ study of Xeloda (capecitabine)vs paclitaxel in breast cancer patients failing previous anthracycline therapy[J]. Proc Am Soc Clin Oncol, 1998,17: 627-635.

共引文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部